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Abstract
Aim
To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea
(SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medi-
cations to metformin (MET) therapy using the data of Korean adults with type-2 diabetes
from the Korean National Health Insurance database.
Methods
We identified 98,383 people who received SU (n = 42,683), DPP-4i (n = 50,310), or TZD (n
= 5,390) added to initial treatment of MET monotherapy in patients with type-2 diabetes.
The main outcome was the hospitalization for HHF. Hazard ratios for HHF by type of sec-
ond-line glucose-lowering medication were estimated by Cox-proportional hazard models.
Sex, age, duration of MET monotherapy, Charlson Comorbidity Index and additional comor-
bidities, and calendar year were controlled as potential confounders.
Results
The observed numbers (rate per 100,000 person-years) of HHF events were 1,129 (658) for
MET+SU users, 710 (455) for MET+DPP-4i users, and 110 (570) for MET+TZD users.
Compared to that for MET+SU users (reference group), the adjusted hazard ratios for HHF
events were 0.76 (95% confidence interval 0.69–0.84) for MET+DPP-4i users and 0.96
(95% confidence interval 0.79–1.17) for MET+TZD users.
Conclusion
DPP-4i as an add-on therapy to MET may lower the risks of HHF compared with SU.
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Introduction
Heart failure (HF) is one of the main health burdens of cardiovascular disease (CVD) in people
with type-2 diabetes mellitus (T2D) [1]. Pathogenic elements central to HF in T2D are hyper-
tension, atherosclerotic vascular disease, and diabetic cardiomyopathy related to insulin resis-
tance. Although HF may be one of several fatal complications of T2D, HF could be
preventable or treatable with drugs [2]. Thus, identifying the appropriate drug for glycemic
control is important in the treatment of T2D to prevent HF.
Metformin (MET) is the most commonly used starting drug for patients with T2D on the
basis of international guidelines [3]. In Korea, MET is the preferred initial oral antidiabetic
drug, and it has also been the most commonly prescribed antidiabetic medication since 2010
[4, 5]. In addition, in 2016,>80% of dual therapy regimens included MET as the first-line ther-
apy. As second-line therapies added to MET, sulfonylurea (SU), dipeptidyl peptidase-4 inhibi-
tor (DPP-4i), and thiazolidinedione (TZD) have been most frequently prescribed in Korea
according to data from the Korean Diabetes Association [4]. MET+SU was the most common
dual therapy protocol until 2014. However, at present, MET+DPP-4i is the most frequently
prescribed dual therapy.
DPP-4i is commonly used because it is associated with a relatively low risk of hypoglycemia
and weight gain [6]. However, there are controversies regarding the HF risk associated with
DPP-4i. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes
Mellitus–Thrombolysis in Myocardial infarction 53 (SAVOR-TIMI 53) trial demonstrated
that saxagliptin was associated with increased rates of hospitalization for HF (HHF) [7]. The
Examination of CV Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial [8]
and the Trial Evaluating CV Outcomes with Sitagliptin trial revealed that alogliptin and sita-
gliptin did not increase the risk of HHF [9]. These discrepancies could have been caused by
the different study designs and populations examined.
Our previous study revealed that MET+DPP-4i for T2D was associated with a lower CVD
risk than that of MET+SU [10]. HF is a frequent and serious comorbidity of T2D that can be
fatal. Considering this, we investigated the effect of DPP-4i and TZD as add-on therapies to
MET in T2D patients on the risk of HHF using real-world data.
Materials and methods
This study was approved by the Institutional Review Board (IRB) of the Yonsei University
Health System (IRB number 4-2015-1023). All datasets were anonymous and de-identified. As
such, the need for informed consent was waived.
Data and study population
The National Health Insurance Service (NHIS) covers approximately 50 million people in
Korea. In the NHIS claims database, diagnoses are coded using the International Classification
of Disease version 10 (ICD-10). Insured individuals are required to undergo general health
screenings every 2 years [11]. The health screening dataset includes information on height,
weight, waist circumference, blood pressure, fasting glucose level, cholesterol level, health
behaviors, and personal history of disease.
In Korea, MET is the most commonly prescribed drug in Korea [5]. MET can be prescribed
as a first-line glucose-lowering treatment for T2D under health insurance coverage when the
patient’s glycated hemoglobin is<53 mmol/mol (7.0%). Dual therapy can be started only if
the glycemic target is not achieved despite MET monotherapy for at least 2–4 months. We
selected T2D (ICD-10 codes E11–E14) and included patients treated with MET monotherapy
for�90 days between January 2009 and December 2012 (n = 397,147) (Fig 1). The main
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exposure was second-line glucose-lowering drugs added to MET for�90 days, and the initia-
tion date of second-line glucose-lowering drugs after MET monotherapy for 90 days was
defined as the index date. We selected individuals aged 30–90 years at the index date. Second-
line glucose-lowering drugs of interest were limited to the three most common drugs: SU,
DPP-4i, and TZD. We excluded individuals who continued MET monotherapy without sec-
ond-line add-on. Then, people prescribed second-line glucose-lowering therapies, including
insulin and drugs other than SU, DPP-4i, and TZD were excluded. We also excluded people
with the event of CVD within 90 days after the index date. Three groups were followed until
Fig 1. Diagram of study flow. MET, metformin; CVD, cardiovascular disease; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione.
https://doi.org/10.1371/journal.pone.0211959.g001
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the end of study, disregarding any regimen changes over time (intention-to-treat). Also, we
used “on-treatment” analysis, which follow-up is censored at the time when the drug is
changed [12]. The study outcome was the first occurrence of HHF (ICD-10: I50). The follow-
up time was defined as the period between the index date and the study outcome. The end of
the study period was 31 December 2015. Patients who died before the end of study date were
censored. Glucose-lowering drugs were identified by the relevant Anatomic Therapeutic
Chemical (ATC) code, a classification system for drugs created by the World Health Organiza-
tion Collaborating Center for Drug Statistics Methodology. The following ATC codes were
used in this study: A10BA02 for MET; A10BB and A10BD02 for SU; A10BH, A10BD07,
A10BD08, A10BD10, A10BD11, A10BD13, and A10BD18 for DPP-4i; and A10BG, A10BD03,
and A10BD05 for TZD.
Covariates
Comorbidities were adjusted using the Charlson Comorbidity Index and calculated by individ-
ual conditions, such as hypertension (ICD-10 codes I10–I15 and/or ATC codes C02–C03 and
C07–C09), dyslipidemia (ICD-10 code E78 and/or ATC code C10), atrial fibrillation (ICD-10
code I48), chronic kidney disease (ICD-10 code N18), and microvascular complications of dia-
betes, including diabetic retinopathy (ICD-10 codes E10.3, E11.3, E12.3, E13.3, E14.3, and
H36.0), diabetic neuropathy (ICD-10 codes E10.4, E11.4, E12.4, E13.4, E14.4, and G63.2), and
diabetic nephropathy (ICD-10 codes E10.2, E11.2, E12.2, E13.2, E14.2, and N08.3). CVD
included myocardial infarction (ICD-10 codes I21–I23), cerebrovascular diseases (ICD-10
codes E10.4, E11.4, E12.4, E13.4, E14.4, and G63.2), unstable angina (ICD-10 code I20.0), HF
(ICD-10 code I50), and transient cerebral ischemic attack (ICD-10 code G45).
A subgroup analysis was performed to account for additional covariates, such as body mass
index (BMI), waist circumference, systolic blood pressure, total cholesterol level, high-density
lipoprotein (HDL) cholesterol level, low-density lipoprotein (LDL) cholesterol level, triglycer-
ide level, fasting glucose level, serum creatinine level, smoking status (non-smoker, former
smoker, or current smoker), and family history of stroke and heart disease. These variables
were measured via health screening within 1 year before the index date. We used available data
from patients who had undergone health screening (n = 35,297).
Statistical analyses
Baseline characteristics were compared between patients treated with the different second-line
glucose-lowering drugs. Cox proportional hazard regression models were used to calculate the
hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of HHF. We tested the
proportional hazards assumption on the basis of Schoenfeld residuals [13]. The MET+SU regimen
was used as a reference group for comparisons with the other second-line regimens. Potential
confounders were sequentially adjusted in two statistical models, as follows: model 1 = sex and
age; model 2 = sex, age, duration of MET therapy, hypertension, dyslipidemia, atrial fibrillation,
chronic kidney disease, microvascular complications of diabetes (retinopathy, neuropathy, and
nephropathy), previous history of CVD, Charlson Comorbidity Index, and calendar index year.
All analyses were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Risk of hospitalization for heart failure by claim data
The patients were divided into the following three groups: MET+SU (n = 42,683), MET+DPP-
4i (n = 50,310), and MET+TZD (n = 5,390). The mean index age of the study population was
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58.3 ± 11.1 years, and 53.4% were men. Compared to MET+SU users, MET+DPP-4i users and
MET+TZD users were younger, had a higher prevalence of microvascular complications such
as diabetic retinopathy, neuropathy, and nephropathy, had a lower prevalence of hypertension,
and had a higher prevalence of dyslipidemia (Table 1). Over 346,991 person-years of follow-
up, 1,949 HHF events were observed. The sex and age-adjusted HR of experiencing an HHF
event was 0.80 (95% CI 0.73–0.88) for MET+DPP-4i therapy compared to MET+SU therapy
(reference). This lower HR risk remained statistically significant after additional adjustments.
The risk of HHF in MET+TZD users (sex and age-adjusted HR 0.94, 95% CI 0.78–1.15) was
lower than that in MET+SU users without statistical significance (Table 2). By using “on-treat-
ment” analysis as mentioned in method, the use of MET+DPP-4i compared to MET+SU was
associated with a 16% lower rate of development of heart failure consistent to the intention-to-
treat that we used (S1 Table). Cumulative risk of HHF was significantly lower in MET+DPP-4i
compared with MET+SU (S1 Fig).
Table 1. Baseline characteristics by type of second-line antidiabetic medication.
Total
(n = 98,383)
MET+SU (n = 42,683) MET+DPP4i (n = 50,310) MET+TZD (n = 5,390)
Men 52,520 (53.4) 22, 581 (52.9) 26,946 (53.6) 2,993 (55.5)
Age, years 58.3 ± 11.1 59.6 ± 11.3 57.2 ± 10.9 57.6 ± 11.1
Inclusion year
2009 49,960 (50.8) 21,827 (51.1) 25,030 (49.8) 3,103 (57.6)
2010 26,278 (26.7) 11,025 (25.8) 13,953 (27.7) 1,300 (24.1)
2011 13,271 (13.5) 5,679 (13.3) 7,000 (13.9) 592 (11.0)
2012 8,874 (9.0) 4,152 (9.7) 4,327 (8.6) 395(7.3)
Comedications
Statin therapy 58,357 (59.3) 22,681 (53.1) 32,229 (64.1) 3,447 (64.0)
ACE inhibitors 5,334 (5.4) 2,683 (6.3) 2,362 (4.7) 289 (5.4)
ARB 54,986 (55.9) 23,978 (56.2) 28,017 (55.7) 2,991 (55.5)
Loop diuretics 5,883 (6.0) 2,986 (7.0) 2,560 (5.1) 337 (6.3)
Beta blockers 20,610 (20.9) 9,568 (22.4) 9,963 (19.8) 1,079 (20.0)
Dihydropyridines 29,692 (30.2) 15,427 (36.1) 12,689 (25.2) 1,576 (29.2)
Non-hydropyridines 3,173 (3.2) 1,343 (3.2) 1,676 (3.3) 154 (2.9)
Low dose acetylic salicylic acid 39,745 (40.4) 18,001 (42.2) 19,659 (39.1) 2,085 (38.7)
Warfarin 1,268 (1.3) 573 (1.3) 643 (1.3) 52 (1.0)
Comorbidities
Hypertension 69,470 (70.6) 30,811 (72.2) 34,906 (69.4) 3,753 (69.6)
Dyslipidemia 70,418 (71.6) 27,489 (64.4) 38,911 (77.3) 4,018(74.6)
Atrial fibrillation 1,780 (1.8) 724 (1.7) 991 (2.0) 102 (1.9)
Chronic kidney disease 779 (0.8) 295 (0.7) 419 (0.8) 65 (1.2)
Diabetic retinopathy 11,416 (11.6) 4,505 (10.6) 6,301 (12.5) 610 (11.3)
Diabetic neuropathy 8,251 (8.4) 3,449 (8.1) 4,336 (8.6) 466 (8.7)
Diabetic nephropathy 4,550 (4.6) 1,313 (3.1) 2,949 (5.9) 288 (5.3)
Cardiovascular disease 16,184 (16.4) 7,227 (16.9) 8,065 (16.0) 892 (16.6)
Charlson score, unit 2.9 ± 1.6 2.8 ± 1.6 2.9 ± 1.6 3.0 ± 1.6
Values are presented as the mean ± standard deviation or n (%). MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione;
ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, aldosterone receptor blocker.
https://doi.org/10.1371/journal.pone.0211959.t001
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Analysis of the risk of HHF stratified by history of CVD
To assess whether a history of CVD affected the relationship between the types of add-on medi-
cation and the risk of HHF, we repeated the analysis separately for people with and those with-
out a history of CVD (Table 3). Compared with use of MET+SU, the use of MET+DPP-4i was
associated with an 18% lower rate of HHF in the group with a history of CVD (HR 0.82, 95% CI
0.70–0.96) and a 28% lower rate of HHF in the group without a history of CVD (HR 0.72; 95%
CI 0.63–0.82). The risk of HHF in MET+TZD users compared to MET+SU was higher in
group with CVD history, and lower in group without CVD history, without significance.
Subgroup analysis using national health screening data
The NHIS claims data included all physician-diagnosed disorders coded by ICD-10 but did
not include objective data on exposure levels to CV risk factors. Therefore, we performed a
subgroup analysis with available health screening data. In total, 35,297 people (35.9%)
remained with available screening data and 498 per 100,000 person-years experienced HHF.
Using MET+SU as a reference group, the HRs for HHF adjusted by age and sex were 0.74
(95% CI 0.61–0.89) for MET+DPP-4i and 1.11 (95% CI 0.77–1.59) for MET+TZD, respectively
(Table 4). Moreover, the lowered HHF risks of the MET+DPP-4i group were also observed in
comparison to the MET+SU group after adjusting for additional covariates. The baseline char-
acteristics of patients treated with the different second-line drugs are shown in S2 Table.
Table 2. Hazard ratios for the development of heart failure by type of second-line antidiabetic medication.
Drugs Person-years No. of cases Event rate
(per 100,000 PY)
Adjusted 1� Adjusted 2†
HR (95% CI) HR (95% CI)
MET+SU 171516 1129 658 1.00 1.00
MET+DPP-4i 156163 710 455 0.80 (0.73–0.88) 0.76 (0.69–0.84)
MET+TZD 19312 110 570 0.94 (0.78–1.15) 0.96 (0.79–1.17)
MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HR, hazard ratio; PY, person-year; CI, confidence interval; no.,
number.
�Adjusted for sex and age.
†Adjusted for sex, age, the duration of metformin therapy, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, microvascular complications of
diabetes (retinopathy, neuropathy, or nephropathy), cardiovascular disease, the Charlson Comorbidity Index, and calendar index year.
https://doi.org/10.1371/journal.pone.0211959.t002
Table 3. Hazard ratios for the development of heart failure by type of second-line antidiabetic medication according to history of cardiovascular disease.
Drugs CVD history (n = 16,184) No CVD history (n = 82,199)
Person-years No. of cases Event rate (per 100,000
PY)
HR (95% CI) Person-years No. of cases Event rate (per 100,000
PY)
HR (95% CI)
MET+SU 27,936 415 1,486 1.00 143,580 714 497 1.00
MET+DPP-
4i
24,100 292 1,212 0.82 (0.70–
0.96)
132,063 418 317 0.72 (0.63–
0.82)
MET+TZD 2,914 45 1,544 1.10 (0.81–
1.50)
16,398 65 396 0.88 (0.68–
1.14)
CVD, cardiovascular disease; MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HR, hazard ratio; CI, confidence
interval; PY, person-year; no., number. Data are adjusted for sex, age, the duration of MET therapy, hypertension, dyslipidemia, atrial fibrillation, chronic kidney
disease, microvascular complications of diabetes (retinopathy, neuropathy, or nephropathy), cardiovascular disease, the Charlson Comorbidity Index, and calendar
index year.
https://doi.org/10.1371/journal.pone.0211959.t003
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Discussion
The present study of nationwide real-world data demonstrated that people with T2D who
were prescribed DPP-4i as a second-line drug alongside MET therapy had relatively lower
risks of HHF than did those who were prescribed SU regardless of their CV history. These
findings were directionally consistent across the subgroups that were available for further anal-
ysis using health screening data. Additionally, people who were prescribed TZD tended to
have lower risks without statistical significance. This result could be explained by the fact that
TZD was not prescribed to people at high risk of HHF because of doctors’ concerns about the
high risks of HHF associated with TZD reported in previous studies [14, 15].
Many previous studies also reported the risk of HHF during monotherapy with glucose-
lowering drugs [16–18]. Fu et al. revealed that individuals treated with DPP-4i had signifi-
cantly lower risks of HHF among patients with no baseline CVD. The risk of HHF was lower
in those treated with DPP-4i monotherapy than SU, pioglitazone, or insulin therapy alone
[19]. When comparing the outcomes of second-line medication added to MET, MET+DPP-4i
yielded a lower HR than MET+SU in terms of all-cause mortality, stroke, cancer, and the com-
bined endpoint [10, 20, 21]. Recently, using Korean NHIS claim data, treatment with DPP-4i
has been shown to be associated with a lower HF risk than treatment with SU [22]. Our previ-
ous study also demonstrated CVD risk reduction associated with MET+DPP-4i treatment for
diabetes when compared to MET+SU [10].
As the NHIS health care utilization database did not include laboratory or anthropometric
parameters, we employed strategies to maximize comparability between the three study
groups. First, we limited our analysis to people treated using only one second-line therapy in
addition to MET. Second, we excluded people who were not prescribed MET monotherapy
before combination therapy or those who used MET monotherapy for<90 days. Third, we
adjusted for the duration of MET monotherapy as a potential confounder. Finally, we per-
formed a subgroup analysis using national health screening data from those who had under-
gone the relevant screening and further adjusted the results for objectively measured bio-
clinical variables. In subgroup analysis, our results confirmed that adding DPP-4i to MET
reduced the incidence of HHF compared to that on using MET+SU. In our population, the
proportion of people with chronic kidney disease and diabetic micro-vascular complications
(retinopathy, neuropathy, and nephropathy) was relatively low, suggesting that these results
could reflect the risk of HHF in the early stage of T2D.
This study has several limitations. First, HHF was defined by an ICD-10 code from the
NHIS health care utilization data, not by clinical or laboratory tests. Thus, there is the
Table 4. Hazard ratios for the development of heart failure by type of second-line antidiabetic medication in patients with available health screening data.
Drugs Person-years No. of cases Event rate
(per 100,000 PY)
Adjusted 1� Adjusted 2†
HR (95% CI) HR (95% CI)
MET+SU 57,209 280 489 1.00 1.00
MET+DPP-4i 59,428 185 311 0.74 (0.61–0.89) 0.65 (0.54–0.79)
MET+TZD 6,949 33 475 1.11 (0.77–1.59) 1.05 (0.73–1.51)
MET, metformin; SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HR, hazard ratio; CI, confidence interval; PY, person-year; no.,
number
�Adjusted for sex and age.
†Adjusted for sex, age, the duration of metformin therapy, body mass index, waist circumference, systolic blood pressure, total cholesterol level, high-density lipoprotein
cholesterol level, low-density lipoprotein cholesterol level, triglyceride level, fasting glucose level, serum creatinine level, smoking status, family history of stroke and
heart disease, history of cardiovascular disease, Charlson Comorbidity Index, and calendar index year.
https://doi.org/10.1371/journal.pone.0211959.t004
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possibility of outcome misclassification. Second, the study had a relatively short follow-up
duration. Further studies are needed to compare the long-term effects of second-line glucose-
lowering drugs. Third, we did not examine safety profiles, such as diabetic ketoacidosis events
or hypoglycemic events, during the follow-up period. Fourth, we did not compare the effects
between the subclasses of DPP-4i. We also could not include new drugs such as sodium-glu-
cose co-transporter-2 inhibitor, which was introduced in 2015, and glucagon-like peptide-1
receptor agonist, which was not covered by health insurance in Korea during the study period.
Comparative studies of new emerging drugs that have recently started to be prescribed are
expected in the near future. Fifth, in contrast to the SAVOR-TIMI 53 trial, in which DPP-4i
was associated with higher risks of HHF, the protective effect of DPP-4i on HHF detected in
this study could have resulted from the fact that we used SU as a reference for comparisons.
Finally, we did not check glycated hemoglobin (HbA1c), reflecting the level of blood sugar
controlled over the past 2 to 3 months, so we only adjusted for fasting glucose level.
Despite these limitations, the current study has several important strengths. The claims
data related to ICD-10 codes and health screening data, which can reflect the biochemical and
anthropometric status of patients, were combined to analyze the differences in the risks of
HHF on using DPP-4i, TZD, and SU as add-on therapies to MET. We confirmed that DPP-4i
added to MET reduced the risk of HHF despite the limitation of defining HHF by an ICD-10
code from NHIS claims data in the subgroup analysis. Smoking status and personal and family
histories of CVD, which were determined via surveys during health screening, were also con-
sidered when analyzing the risk of HHF. This study was performed in a population of patients
who started taking MET at diagnosis, which more closely reflects the common pattern of
administration of oral glucose-lowering drugs under insurance coverage for the relatively early
stages of T2D in Korea. It is worth analyzing the effect of add-on therapy patterns to MET
using real-world data. Finally, we analyzed the risk of HHF people based on an underlying his-
tory of CVD.
Conclusions
An add-on therapy to MET is often required for people with T2D who fail to respond to MET
monotherapy. When trying to achieve glycemic control targets, HHF, a risk associated with
CVD, should be considered when choosing from the available second-line drugs. This study of
nationwide real-world data comparing add-on glucose-lowering medications suggests that
DPP-4i added to MET might lower the risks of HHF compared to SU, irrespective of the
patient’s history of CVD. More investigative studies with longer follow-up durations assessing
the drugs used in the present study or new and emerging drugs such as SGLT-2i or GLP-1 ago-
nist are needed to better reflect real-world practice.
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